Lantheus Holdings, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Lantheus Holdings, Inc.
Tender deadline for Roche acquisition of Spark pushed back to 30 October; 21.4% of Spark shares tendered so far. Vertex further diversifies with fourth deal of 2019 – an RNA-targeted collaboration with Ribometrix.
Lantheus says the all-stock drug-diagnostics deal brings together complementary portfolios of ultrasound and radiopharmaceutical diagnostics with oncology therapeutics.
Derived from Strategic Transactions, Informa's premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech feature highlights notable technology alliances, R&D partnerships and commercial collaborations. This edition covers industry pacts that were signed in March and April 2019.
After knocking Johnson & Johnson off its long-held top position last year, Medtronic has successfully retained the lead in the global medtech market for the second year running in Medtech Insight's MTI 100 rankings. Meanwhile, movement and reshuffling in the ranks continued among other top-tier industry players as they reaped the rewards from previous M&A deals and long-term growth strategies. In this article, we take a closer look at the top-10 overall players, and see who's leapt in front of rivals and who's left eating dust in Medtech Insight's 2017 edition of its annual ranking.
- Radiopharmaceuticals, Contrast Agents
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
- Molecular Imaging
- MRI, NMR
- Diagnostic Imaging Equipment & Supplies
- Other Names / Subsidiaries
- Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc.